Post hoc analysis of the FUTURE 2 study revealed that Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) was sustained at 2 years in patients with psoriatic arthritis (PsA) treated with secukinumab who had achieved remission or LDA at 16 weeks. Remission or LDA occurred at the highest rate in TNF inhibitor-naive patients with PsA, and patients who achieved remission or LDA had a greater improvement in patient-reported outcomes (such as physical function and health-related quality of life) at 2 years than those in whom disease activity remained high.
References
Original article
Coates, L. C. et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results the phase III FUTURE 2 study. Arthritis Res. Ther. 20, 272 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Sustained remission in PsA with secukinumab. Nat Rev Rheumatol 15, 64 (2019). https://doi.org/10.1038/s41584-019-0163-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0163-4